Methylene Blue (MB), following its introduction to biology in the 19th century by Ehrlich, has
found uses in various areas of medicine and biology. At present, MB is the first line of …

The relationship between methylene blue (MB) and Alzheimer's disease (AD) has recently
attracted increasing scientific attention since it has been suggested that MB may slow down …

This paper provides the first review of the memory-enhancing and neuroprotective metabolic
mechanisms of action of methylene blue in vivo. These mechanisms have important …

Since it was first synthesised in 1876, Methylene Blue (MB) has found uses in many different
areas of clinical medicine, ranging from dementia to cancer chemotherapy. In addition, MB …

Methylene blue (MB) is a well-established drug with a long history of use, owing to its
diverse range of use and its minimal side effect profile. MB has been used classically for the …

Methylene blue (MB) has been shown to act at multiple cellular and molecular targets and
as a result possesses diverse medical applications. Among these is a high potency …

Promising results have emerged from a phase II clinical trial testing methylene blue (MB) as
a potential therapeutic for Alzheimer disease (AD), where improvements in cognitive …

The key cytopathologies in the brains of Alzheimer's disease (AD) patients include
mitochondrial dysfunction and energy hypometabolism, which are likely caused by the …

Methylene blue (MB) is a diaminophenothiazine with potent antioxidant and unique redox
properties that prevent morphologic degenerative changes in the mouse retina induced by …

Methylene blue (MB) increases mitochondrial oxygen consumption and restores memory
retention in rats metabolically impaired by inhibition of cytochrome c oxidase. This study …